medigraphic.com
SPANISH

Salud Mental

ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2017, Number 5

Next >>

Salud Mental 2017; 40 (5)

What do we know about the relationship between attention deficit hyperactivity disorder and substance use disorders?

Yule AM, Biederman J
Full text How to cite this article

Language: English
References: 7
Page: 181-182
PDF size: 114.64 Kb.


Key words:

No keywords

Text Extraction

While it is well documented that attention deficit hyperactivity disorder (ADHD) and substance use disorders (SUD) commonly co-occur, little is known about the reasons for this association. Since genetic influences are operant in both disorders, one hypothesis is that the co-occurrence of the disorders is due to common genes. One way to assess for a genetic relationship between ADHD and SUD is through a familial risk analysis. A familial risk analysis compares the prevalence of an illness in relatives of individuals with a given disorder based on the presence or absence of the same illness in relatives. Since both ADHD and addiction are known to be familial illnesses, we can expect relatives of individuals with ADHD and addiction to have a higher prevalence of the same disorders.


REFERENCES

  1. Biederman, J., Monuteaux, M., Mick, E., Wilens, T., Fontanella, J., Poetzl, K., ... Faraone, S. (2006). Is cigarette smoking a gateway drug to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity Desorder. Biological Psychiatry, 59(3), 258-264.

  2. Biederman, J., Petty, C. R., Hammerness, P., Batchelder, H., & Faraone, S. V. (2012). Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. The British Journal of Psychiatry, 201(3), 207-214. doi:10.1192/bjp.bp.111.100339

  3. Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104(2), e20.

  4. McCabe, S. E., Dickinson, K., West, B. T., & Wilens, T. E. (2016). Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. Journal of the American Academy of Child & Adolescent Psychiatry, 55(6), 479-486. doi:10.1016/j.jaac.2016.03.011

  5. Wilens, T., Faraone, S., Biederman, J., & Gunawardene, S. (2003). Does stimulant therapy of ADHD beget later substance abuse: A meta-analytic review of the literature. Pediatrics, 111(1), 179-185.

  6. Yule, A. (2013). The Impact of Exposure to Parental Substance Use Disoders on Substance Use Disorder Risk in Growing-Up Boys and Girls. Poster presented at the American Academy of Child and Adolescent Psychiatry, Orlando.

  7. Yule, A. M., Martleon, M., Faraone, S., Carrellas, N., Wilens, T. E., & Biederman, J. (2017). Examining the association between attention deficit hyperactivity disorder and substance use disorders: a familial risk analysis. Journal of Psychiatric Research (85), 49-55.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Salud Mental. 2017;40